Molecular hydrogen suppresses reactive astrogliosis related to oxidative injury during spinal cord injury in rats

Fang-Ting Liu, Hong-Bun Yuan, Jian Li, Sheng-Ming Xu, Xiang-Nan Li, Xue-Jun Sun, Zheng-Hua Xiang

Read more:

DOI: 10.1111/cns.12258 DOI is the universal ID for this study.

This link will take you to the full study.


Aims: Spinal cord injury (SCI) can induce excessive astrocyte activation. Hydrogen has been deemed as a novel antioxidant. We investigated whether molecular hydrogen could act as an antiastrogliosis agent during SCI and oxidative injury in experimental rats and cultured astrocytes.

Methods: Hydrogen-rich saline (HS, 8 mL/kg, i.p.) was injected every 12 h after SCI in rats. The expression of STAT3, p-STAT3, and glial fibrillary acidic protein (GFAP); the release of IL-1β, IL-6, and TNF-α; and astrogliosis, along with the BBB score, were evaluated. Culturing astrocytes with hydrogen-rich medium, the intracellular reactive oxygen species (ROS), astrogliosis, and the release of proinflammatory cytokines were assessed after H2O2-induced injury.

Results: In the HS group, the expression of STAT3, p-STAT3, and GFAP and the proinflammatory cytokines were decreased in local spinal cord on postoperation day (POD) 3; on PODs 7 and 14, reactive astrogliosis was suppressed, and the locomotor function was also improved. Furthermore, hydrogen-rich medium attenuated the intracellular production of ROS (especially HO•), astrogliosis, and the secretion of proinflammatory cytokines in astrocytes 12 h after H2O2-induced injury. Conclusions: Molecular hydrogen could suppress reactive astrogliosis after contusive SCI and reduce the release of proinflammatory cytokines produced by active astrocytes related to oxidative injury. Thus, molecular hydrogen is potential to be a neuroprotective agent.

Publish Year 2014
Country China
Rank Positive
Journal CNS Neuroscience and Therapeutics
Primary Topic Spine
Secondary TopicSpinal Cord Injury
Model Rat
Tertiary TopicOxidative Stress
Vehicle Saline (Dissolved)
pH Neutral
Application Injection